- Policy
- "Synthetic Biology" that Moderna used
- by Kang, Shin-Kook Nov 2, 2022 05:36am
- The Act on Research Promotion and Support for Synthetic Biology' proposed legislation in the first half of next year. Support measures will be prepared for Synthetic Biology, which is evaluated to double the efficiency of research and development of innovative new drugs and materials. Deputy Prime Minister for Economic Affairs and Minister of
- Policy
- LG Chemical completed Vimovo's domestic copyright
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- LG Chem has acquired the domestic copyright of the complex "Vimovo," which combines NSAIDs-based anti-inflammatory analgesics (Naproxen) and PPI-based gastroesophageal reflux disease treatment ingredient Esomeprazole. Vimovo is a product released in Korea by AstraZeneca Korea in 2012 and has been jointly selling it with LG Chem. As Vimovo'
- Policy
- It doesn't mean that we're considering a reduction
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- The Ministry of Health and Welfare explained in writing about Minister Cho Kyu-hong's answer to the government audit site on the 6th about Korea's generic insurance drug price, which was set at an expensive price. The remarks at the time came as Choi Jae-hyung, a lawmaker of the People's Power, responded to a question that "the price of gener
- Policy
- Gov’t to fully investigate its COVID-19 research support
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- The Ministry of Health and Welfare announced that it will conduct a full investigation on all of the projects it had supported for the clinical trial research of COVID-19 treatments and vaccines by the first quarter of next year. Since 2020, a total of 10 companies were selected for the government's COVID-19 treatment and vaccine clinical
- Policy
- It takes 218 days to register after applying for a new drug
- by Kim, Jung-Ju Oct 31, 2022 06:07am
- Among the new drugs introduced in Korea, drugs that started the payroll process from insurance application to registration last year took an average of 218 days. Among them, the treatment for rare diseases took 238 days and the anticancer drug took 227 days. Considering that the legal processing period is 7 months (210 days), the government emph
- Policy
- Koselugo & Retevmo's benefit registration can be shortened
- by Lee, Tak-Sun Oct 31, 2022 06:06am
- The registration of drug benefits such as Koselugo and Retevmo, which are currently under evaluation, is expected to be shortened by 30 days. This is because the NHIS and the HIRA have decided to shorten the benefit registration period for drugs used in life-threatening diseases. Koselugo and Retevmo are drugs licensed through the Ministry of
- Policy
- The warning phrase deleting the possibility of Nucynta abuse
- by Lee, Hye-Kyung Oct 27, 2022 05:52am
- The "possibility of abuse," a warning phrase for narcotic painkillers containing Tapentadol, will be deleted. The permit includes a new disorder of resistance and opioid use, and monitoring and addiction patients consider consulting with experts. The Ministry of Food and Drug Safety announced that it will prepare a proposal for a change in pe
- Policy
- Permission for Libtayo, a tx for skin squamous cell cancer
- by Lee, Hye-Kyung Oct 26, 2022 05:50am
- The Ministry of Food and Drug Safety (Director Oh Yu-kyung) announced on the 25th that it has approved Libtayo, a rare drug from Sanofi-Aventis Korea, for skin squamous cell cancer treatment. Libtayo is a monoclonal antibody targeting cell predetermined history 1 (PD-1)*, an immune gateway receptor for immune cells (T cells). Programmed cell
- Policy
- Price cut of Faslodex
- by Lee, Tak-Sun Oct 26, 2022 05:50am
- AstraZeneca's breast cancer treatment, Faslodex, will be a real match with Boryung's first generic Fulvet as it will be cut by 30% from the current upper limit starting next month due to a cut in drug prices following its entry into the generic. This is because the price has become almost similar to Boryung Fulvet, which has the same ingredie
- Policy
- Lenvima's PMS results for 6 years
- by Lee, Hye-Kyung Oct 25, 2022 05:45am
- The permission of Lenvima, a thyroid-targeted anticancer drug, will be changed based on the results of a six-year post-marketing survey conducted in Korea. The Ministry of Food and Drug Safety will prepare a change order (proposal) based on the results of the post-marketing investigation of Lenvima by Eisai Korea and conduct an opinion inqui
